Fosun Licenses Immunology Asset FXS6837 to Sitala in $670M Deal

Shanghai Fosun Pharmaceutical has signed a licensing agreement worth up to $670 million with UK-based Sitala Bio for an immunology asset.1

The specific molecule involved is FXS6837, a small molecule inhibitor for inflammation and autoimmune diseases.2

Under the terms, Sitala receives exclusive global rights (excluding Mainland China, Hong Kong SAR, and Macau SAR) to develop, manufacture, and commercialize FXS6837 and related products.2

Fosun will retain commercialization rights for FXS6837 in Mainland China, Hong Kong, and Macau.2

The total potential deal value includes $5 million in Sitala shares and up to $190 million in specified milestone payments to Fosun, as part of a broader package totaling up to $670 million (likely including sales milestones and royalties).41

The licensed indication covers both human and animal diseases in the diagnosis and treatment fields.2

This partnership demonstrates increasing international licensing activity by Fosun in the immune/inflammation drug development sector.12

Sources:

1. https://firstwordpharma.com/story/5992526

2. https://www.thepharmaletter.com/biotechnology/fosun-pharma-out-licenses-fxs6837-to-sitala

4. https://www.tradingview.com/news/reuters.com,2025:newsml_L4N3UI0PZ:0-shanghai-fosun-pharma-says-unit-signs-licensing-agreement-with-sitala/